Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 629-638

  Tachimori, Akiko ^a   Yamada, Nobuya ^a   Amano, Ryosuke ^a   Ohira, Masaichi ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal carcinoma; COX 2 inhibitor; Liver metastasis; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; FLUOROURACIL; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; CELL INVASION; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DRUG COMBINATIONS; ETODOLAC; FEMALE; HUMANS; LACTONES; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM METASTASIS; OXONIC ACID; SULFONES; TEGAFUR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42549145438     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. August DA, Sugarbaker PH, Ottow RT, Gianola FJ and Schneider PD: Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival. Ann Surg 201: 210-218, 1985.
2. Rodgers MS and McCall JL: Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review. Br J Surg 87: 1142-1155, 2000.
3. Martin LW and Warren RS: Current management of colorectal liver metastases. Surg Oncol Clin N Am 9: 853-876, 2000.
4. Penna C and Nordlinger B: Colorectal metastasis (liver and lung). Surg Clin North Am 82: 1075-1090, 2002.
5. Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, Mochizuki H and Yamamoto J: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46: 22-31, 2003.
6. Malet-Martino M and Martino R: Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 7: 288-323, 2002.
7. Johnston PG and Kaye S: Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 12: 639-646, 2001.
8. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996.
9. Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009, 1993.
10. Vinogradova Y, Hippisley-Cox J, Coupland C and Logan RF: Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-contorol study. Gastroebterology 133: 393-402, 2007.
11. Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
12. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC and Speizer FE: Aspirin and the risk of colorectal cancer in women. N Engl J Med 333: 609-614, 1995.
13. Suh O, Mettlin C and Petrelli NJ: Aspirin use, cancer, and polyps of the large bowel. Cancer 72: 1171-1177, 1993.
14. Peleg, II, Maibach HT, Brown SH and Wilcox CM: Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154: 394-399, 1994.
15. Hisamuddin IM, Wehbi MA, Chao A, Wyre HW, Hylind LM, Giardiello FM and Yang VW: Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res 10: 8357-8362, 2004.
16. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR and Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993.
17. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
18. Smith WL, DeWitt DL and Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
19. Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916, 1999.
20. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994.
21. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M and Hla T: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
22. Yao M, Lam EC, Kelly CR, Zhou W and Wolfe MM: Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer 90: 712-719, 2004.
23. Erickson BA, Longo WE, Panesar N, Mazuski JE and Kaminski DL: The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 81: 101-107, 1999.
24. Li M, Wu X and Xu XC: Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 7: 1010-1016, 2001.
25. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI and Rigas B: Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin- independent pathway. Biochem Pharmacol 52: 237-245, 1996.
26. Williams CS, Watson AJ, Sheng H, Helou R, Shao J and DuBois RN: Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 60: 6045-6051, 2000.
27. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998.
28. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J and Yang WK: Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 91: 894-899, 2001.
29. Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340, 1997.
30. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ and Patierno SR: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60: 4629-4637, 2000.
31. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998.
32. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ and Tarnawski AS: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418-1423, 1999.
33. Kobayashi H, Gonda T, Uetake H, Higuchi T, Enomoto M and Sugihara K: JTE-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: a vascular cast model study. Int J Cancer 112: 920-926, 2004.
34. Nagatsuka I, Yamada N, Shimizu S, Ohira M, Nishino H, Seki S and Hirakawa K: Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer. Int J Cancer 100: 515-519, 2002.
35. Yamada N, Chung YS, Takatsuka S, Arimoto Y, Sawada T, Dohi T and Sowa M: Increased sialyl Lewis A expression and fucosyltransferase activity with acquisition of a high metastatic capacity in a colon cancer cell line. Br J Cancer 76: 582-587, 1997.
36. Taguchi T: Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU. Oncology 54(Suppl 1): 12-18, 1997.
37. Nishimura G, Yanoma S, Mizuno H, Kawakami K and Tsukuda M: A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 90: 1152-1162, 1999.
38. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S and Kawai S: Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 531: 278-284, 2002.
39. Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M, Ishikawa H, Hamasaki K, Nakata K and Eguchi K: Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology 35: 1117-1124, 2002.
40. Konno H, Tanaka T, Baba M, Kanai T, Matsumoto K, Kamiya K and Nakamura S: Therapeutic effect of 1 M tegafur -0.4 M 5-chloro-2,4-dihydroxypyridine -1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. Jpn J Cancer Res 90: 448-453, 1999.